tiprankstipranks
Trending News
More News >
Adaptive Biotechnologies (ADPT)
:ADPT
US Market
Advertisement

Adaptive Biotechnologies (ADPT) Stock Forecast & Price Target

Compare
942 Followers
See the Price Targets and Ratings of:

ADPT Analyst Ratings

Strong Buy
7Ratings
Strong Buy
6 Buy
1 Hold
0 Sell
Based on 7 analysts giving stock ratings to
Adaptive
Biotechnologies
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ADPT Stock 12 Month Forecast

Average Price Target

$13.80
▲(24.89% Upside)
Based on 7 Wall Street analysts offering 12 month price targets for Adaptive Biotechnologies in the last 3 months. The average price target is $13.80 with a high forecast of $15.00 and a low forecast of $11.00. The average price target represents a 24.89% change from the last price of $11.05.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","16":"$16","6.25":"$6.25","9.5":"$9.5","12.75":"$12.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,6.25,9.5,12.75,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.33,10.68923076923077,11.048461538461538,11.407692307692308,11.766923076923078,12.126153846153846,12.485384615384616,12.844615384615384,13.203846153846154,13.563076923076924,13.922307692307692,14.281538461538462,14.64076923076923,{"y":15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.33,10.596923076923076,10.863846153846154,11.13076923076923,11.397692307692308,11.664615384615384,11.931538461538462,12.198461538461538,12.465384615384616,12.732307692307693,12.99923076923077,13.266153846153847,13.533076923076923,{"y":13.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.33,10.381538461538462,10.433076923076923,10.484615384615385,10.536153846153846,10.587692307692308,10.63923076923077,10.69076923076923,10.742307692307692,10.793846153846154,10.845384615384615,10.896923076923077,10.948461538461538,{"y":11,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.45,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.7,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.02,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.31,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.53,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.75,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.26,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.52,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.36,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.55,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.19,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$15.00Average Price Target$13.80Lowest Price Target$11.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on ADPT
TipRanks AITipRanks
Not Ranked
TipRanks
$11.5
Hold
4.07%
Upside
Reiterated
08/06/25
The overall stock score is primarily influenced by the company's financial performance challenges, despite positive earnings call results and technical momentum. The negative P/E ratio and lack of dividend yield further weigh on the score.
TD Cowen
$13$15
Buy
35.75%
Upside
Assigned
08/06/25
Adaptive Biotechnologies: Strong Financial Performance and Strategic Initiatives Drive Optimistic Outlook
William Blair Analyst forecast on ADPT
Andrew BrackmannWilliam Blair
William Blair
Buy
Reiterated
08/06/25
Strong Financial Performance and Growth Potential Drive Buy Rating for Adaptive Biotechnologies
J.P. Morgan Analyst forecast on ADPT
Rachel VatnsdalJ.P. Morgan
J.P. Morgan
$10$14
Buy
26.70%
Upside
Reiterated
08/06/25
Analysts' Top Healthcare Picks: Cogent Biosciences (COGT), Adaptive Biotechnologies (ADPT)
BTIG
$13$14
Buy
26.70%
Upside
Reiterated
08/06/25
BTIG Sticks to Their Buy Rating for Adaptive Biotechnologies (ADPT)
Craig-Hallum Analyst forecast on ADPT
William BonelloCraig-Hallum
Craig-Hallum
Buy
Reiterated
08/04/25
Adaptive Biotechnologies (ADPT) Receives a Buy from Craig-Hallum
Piper Sandler Analyst forecast on ADPT
David WestenbergPiper Sandler
Piper Sandler
$13
Buy
17.65%
Upside
Reiterated
06/12/25
Analysts Offer Insights on Healthcare Companies: Taysha Gene Therapies (NASDAQ: TSHA), Soleno Therapeutics (NASDAQ: SLNO) and Adaptive Biotechnologies (NASDAQ: ADPT)
Morgan Stanley Analyst forecast on ADPT
Tejas SavantMorgan Stanley
Morgan Stanley
$7$9
Hold
-18.55%
Downside
Reiterated
05/05/25
Adaptive Biotechnologies: Strong Q1 Performance but Hold Rating Due to Valuation Concerns
Scotiabank Analyst forecast on ADPT
Sung Ji NamScotiabank
Scotiabank
$12
Buy
8.60%
Upside
Reiterated
05/05/25
Scotiabank Keeps Their Buy Rating on Adaptive Biotechnologies (ADPT)
Goldman Sachs Analyst forecast on ADPT
Matthew SykesGoldman Sachs
Goldman Sachs
$8$9
Buy
-18.55%
Downside
Upgraded
03/21/25
Adaptive Biotechnologies (ADPT) was upgraded to a Buy Rating at Goldman Sachs
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on ADPT
TipRanks AITipRanks
Not Ranked
TipRanks
$11.5
Hold
4.07%
Upside
Reiterated
08/06/25
The overall stock score is primarily influenced by the company's financial performance challenges, despite positive earnings call results and technical momentum. The negative P/E ratio and lack of dividend yield further weigh on the score.
TD Cowen
$13$15
Buy
35.75%
Upside
Assigned
08/06/25
Adaptive Biotechnologies: Strong Financial Performance and Strategic Initiatives Drive Optimistic Outlook
William Blair Analyst forecast on ADPT
Andrew BrackmannWilliam Blair
William Blair
Buy
Reiterated
08/06/25
Strong Financial Performance and Growth Potential Drive Buy Rating for Adaptive Biotechnologies
J.P. Morgan Analyst forecast on ADPT
Rachel VatnsdalJ.P. Morgan
J.P. Morgan
$10$14
Buy
26.70%
Upside
Reiterated
08/06/25
Analysts' Top Healthcare Picks: Cogent Biosciences (COGT), Adaptive Biotechnologies (ADPT)
BTIG
$13$14
Buy
26.70%
Upside
Reiterated
08/06/25
BTIG Sticks to Their Buy Rating for Adaptive Biotechnologies (ADPT)
Craig-Hallum Analyst forecast on ADPT
William BonelloCraig-Hallum
Craig-Hallum
Buy
Reiterated
08/04/25
Adaptive Biotechnologies (ADPT) Receives a Buy from Craig-Hallum
Piper Sandler Analyst forecast on ADPT
David WestenbergPiper Sandler
Piper Sandler
$13
Buy
17.65%
Upside
Reiterated
06/12/25
Analysts Offer Insights on Healthcare Companies: Taysha Gene Therapies (NASDAQ: TSHA), Soleno Therapeutics (NASDAQ: SLNO) and Adaptive Biotechnologies (NASDAQ: ADPT)
Morgan Stanley Analyst forecast on ADPT
Tejas SavantMorgan Stanley
Morgan Stanley
$7$9
Hold
-18.55%
Downside
Reiterated
05/05/25
Adaptive Biotechnologies: Strong Q1 Performance but Hold Rating Due to Valuation Concerns
Scotiabank Analyst forecast on ADPT
Sung Ji NamScotiabank
Scotiabank
$12
Buy
8.60%
Upside
Reiterated
05/05/25
Scotiabank Keeps Their Buy Rating on Adaptive Biotechnologies (ADPT)
Goldman Sachs Analyst forecast on ADPT
Matthew SykesGoldman Sachs
Goldman Sachs
$8$9
Buy
-18.55%
Downside
Upgraded
03/21/25
Adaptive Biotechnologies (ADPT) was upgraded to a Buy Rating at Goldman Sachs
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Adaptive Biotechnologies

1 Month
xxx
Success Rate
8/17 ratings generated profit
47%
Average Return
-1.59%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 47.06% of your transactions generating a profit, with an average return of -1.59% per trade.
3 Months
xxx
Success Rate
11/17 ratings generated profit
65%
Average Return
+2.48%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 64.71% of your transactions generating a profit, with an average return of +2.48% per trade.
1 Year
Rachel VatnsdalJ.P. Morgan
Success Rate
8/11 ratings generated profit
80%
Average Return
+67.07%
reiterated a buy rating 2 days ago
Copying Rachel Vatnsdal's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +67.07% per trade.
2 Years
xxx
Success Rate
12/17 ratings generated profit
71%
Average Return
+56.35%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 70.59% of your transactions generating a profit, with an average return of +56.35% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ADPT Analyst Recommendation Trends

Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
0
0
0
0
0
Buy
11
13
12
11
4
Hold
5
8
10
12
9
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
16
21
22
23
13
In the current month, ADPT has received 4 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. ADPT average Analyst price target in the past 3 months is 13.80.
Each month's total comprises the sum of three months' worth of ratings.

ADPT Financial Forecast

ADPT Earnings Forecast

Next quarter’s earnings estimate for ADPT is -$0.21 with a range of -$0.24 to -$0.19. The previous quarter’s EPS was -$0.17. ADPT beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year ADPT has Preformed in-line its overall industry.
Next quarter’s earnings estimate for ADPT is -$0.21 with a range of -$0.24 to -$0.19. The previous quarter’s EPS was -$0.17. ADPT beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year ADPT has Preformed in-line its overall industry.

ADPT Sales Forecast

Next quarter’s sales forecast for ADPT is $55.52M with a range of $54.20M to $58.00M. The previous quarter’s sales results were $58.88M. ADPT beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.64% of the time in the same period. In the last calendar year ADPT has Preformed in-line its overall industry.
Next quarter’s sales forecast for ADPT is $55.52M with a range of $54.20M to $58.00M. The previous quarter’s sales results were $58.88M. ADPT beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.64% of the time in the same period. In the last calendar year ADPT has Preformed in-line its overall industry.

ADPT Stock Forecast FAQ

What is ADPT’s average 12-month price target, according to analysts?
Based on analyst ratings, Adaptive Biotechnologies’s 12-month average price target is 13.80.
    What is ADPT’s upside potential, based on the analysts’ average price target?
    Adaptive Biotechnologies has 24.89% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ADPT a Buy, Sell or Hold?
          Adaptive Biotechnologies has a consensus rating of Strong Buy which is based on 6 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Adaptive Biotechnologies’s price target?
            The average price target for Adaptive Biotechnologies is 13.80. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $15.00 ,the lowest forecast is $11.00. The average price target represents 24.89% Increase from the current price of $11.05.
              What do analysts say about Adaptive Biotechnologies?
              Adaptive Biotechnologies’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of ADPT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis